Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 316 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Nivolumab Injections Could Make Treatment Easier for More People with Cancer March 13, 2024 Cómo comenzar a hacer ejercicio en el hogar durante el tratamiento... January 18, 2023 Not Old Enough for Breast Cancer, She Demanded a Mammogram Anyway... September 16, 2020 Can Being Exposed to Wildfire Smoke Affect Your Cancer Risk? February 1, 2024 Load more HOT NEWS FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... ctDNA-Guided Treatment Influence on Survival in Advanced NSCLC How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment...
